Related Experiment Video
Updated: Jun 22, 2026

Dioscin Mediated IgA Nephropathy Alleviation by Inhibiting B Cell Activation In Vivo and Decreasing Galactose-Deficient IgA1 Production In Vitro
Published on: October 13, 2023
Immunoglobulin A nephropathy in China: progress and challenges.
Guang-Yan Cai1, Xiang-Mei Chen
1Department of Nephrology, PLA General Hospital, Beijing, PR China.
IgA nephropathy (IgAN) in China presents unique challenges. Research highlights genetic factors, clinical features, and treatment strategies, emphasizing the need for further multicenter trials to improve patient outcomes.
Area of Science:
- Nephrology
- Immunology
- Genetics
Background:
- IgA nephropathy (IgAN) is the most prevalent primary glomerulonephritis in China.
- A significant percentage of patients develop renal insufficiency within a decade, imposing a substantial burden.
Purpose of the Study:
- To review and analyze IgAN research in China.
- To compare Chinese data with international findings.
- To characterize IgAN in the Chinese population.
Main Methods:
- Comprehensive review of basic and clinical research conducted in China.
- Comparative analysis of epidemiological and clinical data between China and other countries.
Main Results:
- Identified genetic variations linked to IgAN susceptibility and progression.
- Characterized specific clinical presentations in Chinese IgAN patients, including hypertension and specific lesions.
- Demonstrated superior efficacy of combined therapies (urokinase + ACEI or steroid + ACEI) over ACEI alone for proteinuria reduction and renal protection.
Conclusions:
- IgA nephropathy poses a significant challenge for Chinese nephrologists.
- Further in-depth basic research and large-scale multicenter clinical trials are crucial for advancing IgAN management in China.
More Related Videos
Related Concept Videos
Nephrotic Syndrome I : Introduction
Diabetic Nephropathy
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease I: Introduction
Nephrotic Syndrome III : Nursing Management
Nephrotic Syndrome II : Assessment and Medical Management

